<DOC>
	<DOCNO>NCT01314872</DOCNO>
	<brief_summary>This 2-part study ass vibegron ( MK-4618 ) reduce number daily urination effectively placebo participant overactive bladder ( OAB ) . The primary hypothesis base study administration vibegron demonstrate dose-related reduction , compare placebo , average number daily micturition participant OAB 8 week treatment .</brief_summary>
	<brief_title>A Study Efficacy Safety Vibegron ( MK-4618 ) Participants With Overactive Bladder ( OAB ) ( MK-4618-008 )</brief_title>
	<detailed_description>All participant receive placebo ( run-in ) 1 week prior randomization Parts 1 2 . Participants complete base study may screen year-long , multicenter extension assessment long-term safety efficacy .</detailed_description>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<criteria>If participant reproductive potential , must agree remain abstinent use ( his/her partner use ) 2 acceptable method birth control within project duration study Clinical history OAB least 3 month meet either OAB wet OAB dry criterion Is able read , understand complete questionnaire void diary without assistance Is ambulatory good general physical mental health No clinically significant electrocardiogram laboratory abnormality If female , currently pregnant breastfeeding , expect conceive within project duration study Evidence diabetes insipidus , uncontrolled hyperglycemia uncontrolled hypercalcemia Allergy , intolerance , history significant clinical laboratory adverse experience associate active inactive component tolterodine ER vibegron ( MK4618 ) formulation ; history active diagnosis condition contraindicate tolterodine ER prescribing label Has low urinary tract pathology could responsible urgency , frequency , incontinence History injury , surgery , neurodegenerative disease ( e.g. , multiple sclerosis ) could affect low urinary tract nerve supply History continual urine leakage Surgery correct stress urinary incontinence pelvic organ prolapse within 6 month Known history elevate postvoid residual Bladder training electrostimulation within 2 week plan initiate either procedure study Active recurrent ( &gt; 6 episode per year ) urinary tract infection Current hematuria Required use indwell catheter require intermittent catheterization History fecal incontinence</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Overactive bladder</keyword>
	<keyword>MK-4618</keyword>
	<keyword>tolterodine</keyword>
</DOC>